BR112016021641A2 - Potentes inibidores da epóxido hidrolase solúveis - Google Patents

Potentes inibidores da epóxido hidrolase solúveis

Info

Publication number
BR112016021641A2
BR112016021641A2 BR112016021641A BR112016021641A BR112016021641A2 BR 112016021641 A2 BR112016021641 A2 BR 112016021641A2 BR 112016021641 A BR112016021641 A BR 112016021641A BR 112016021641 A BR112016021641 A BR 112016021641A BR 112016021641 A2 BR112016021641 A2 BR 112016021641A2
Authority
BR
Brazil
Prior art keywords
epoxide hydrolase
powerful
soluble epoxide
hydrolase inhibitors
inhibitors
Prior art date
Application number
BR112016021641A
Other languages
English (en)
Inventor
D Hammock Bruce
Sing Stephen Lee Kin
Bora Inceoglu Ahmet
Original Assignee
Eicosis Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eicosis Llc filed Critical Eicosis Llc
Publication of BR112016021641A2 publication Critical patent/BR112016021641A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

POTENTES INIBIDORES DA EPÓXIDO HIDROLASE SOLÚVEIS. A presente invenção refere-se a uma nova série de inibidores da epóxido hidrolase solúvel (sEH) com propriedades físicas melhoradas que intensificam sua probabilidade a fármaco para tratar doenças associadas a sEH, tal como dor neuropática diabética crônica.
BR112016021641A 2014-03-27 2015-03-27 Potentes inibidores da epóxido hidrolase solúveis BR112016021641A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461971410P 2014-03-27 2014-03-27
PCT/US2015/023048 WO2015148954A1 (en) 2014-03-27 2015-03-27 Potent soluble epoxide hydrolase inhibitors

Publications (1)

Publication Number Publication Date
BR112016021641A2 true BR112016021641A2 (pt) 2017-08-15

Family

ID=54196453

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016021641A BR112016021641A2 (pt) 2014-03-27 2015-03-27 Potentes inibidores da epóxido hidrolase solúveis

Country Status (9)

Country Link
US (1) US10377744B2 (pt)
EP (1) EP3129023B1 (pt)
CN (2) CN106163521B (pt)
AU (1) AU2015237245B2 (pt)
BR (1) BR112016021641A2 (pt)
DK (1) DK3129023T3 (pt)
ES (1) ES2871027T3 (pt)
PL (1) PL3129023T3 (pt)
WO (1) WO2015148954A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021026376A2 (pt) 2019-06-25 2022-05-10 Gilead Sciences Inc Proteínas de fusão flt3l-fc e métodos de uso
EP4349413A2 (en) 2019-10-18 2024-04-10 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
CA3153636A1 (en) 2019-10-31 2021-05-06 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
IL294032A (en) 2019-12-24 2022-08-01 Carna Biosciences Inc Compounds that regulate diacylglycerol kinase
AU2021219668A1 (en) 2020-02-14 2022-08-25 Gilead Sciences, Inc. Antibodies and fusion proteins that bind to CCR8 and uses thereof
CR20220547A (es) 2020-05-01 2022-12-15 Gilead Sciences Inc Compuestos de 2,4-dioxopirimidina inhibidores de cd73
CN111574432A (zh) * 2020-06-17 2020-08-25 安徽省逸欣铭医药科技有限公司 一种可溶性环氧水解酶和γ-氨基丁酸双重抑制剂及用途
US20240024302A1 (en) * 2020-10-26 2024-01-25 Beth Israel Deaconess Medical Center, Inc. SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS AND DUAL COX/sEH INHIBITORS FOR THE TREATMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY
EP4063348A1 (en) 2021-03-24 2022-09-28 Universitat de Barcelona Compounds as soluble epoxide hydrolase inhibitors
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
CN113264922A (zh) * 2021-05-22 2021-08-17 深圳市术理科技有限公司 降解sEH的小分子化合物或其可药用的盐、制备方法及用途
CN113402447B (zh) * 2021-06-22 2022-10-18 沈阳药科大学 一种sEH抑制剂或其药学上可接受的组合物及其制备方法和应用
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
KR20240025616A (ko) 2021-06-23 2024-02-27 길리애드 사이언시즈, 인코포레이티드 다이아실글리세롤 키나제 조절 화합물
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240023628A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
TW202330504A (zh) 2021-10-28 2023-08-01 美商基利科學股份有限公司 嗒𠯤—３（２ｈ）—酮衍生物
CA3235986A1 (en) 2021-10-29 2023-05-04 Gilead Science, Inc. Cd73 compounds
US20230242508A1 (en) 2021-12-22 2023-08-03 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
EP4245756A1 (en) 2022-03-17 2023-09-20 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023183817A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
TW202400138A (zh) 2022-04-21 2024-01-01 美商基利科學股份有限公司 Ｋｒａｓ ｇ１２ｄ調節化合物
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5445956A (en) 1993-08-13 1995-08-29 The Regents Of The University Of California Recombinant soluble epoxide hydrolase
US8815951B2 (en) 1996-08-13 2014-08-26 The Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of inflammation
BR0314392A (pt) 2002-09-16 2005-07-12 Glaxo Group Ltd Composto ou um sal do mesmo, composição farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deficiência cognitiva em um mamìfero, e, combinação
CA2559665A1 (en) 2004-03-16 2005-09-29 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
AU2005295167B2 (en) 2004-10-20 2012-05-10 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
AR059826A1 (es) 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
CN101535259A (zh) * 2006-10-20 2009-09-16 亚瑞特医疗公司 作为可溶性环氧化物水解酶抑制剂的苯基脲化合物
JP2010507586A (ja) * 2006-10-20 2010-03-11 アレテ セラピューティクス， インコーポレイテッド 可溶性エポキシドヒドロラーゼ阻害剤
WO2009062073A1 (en) 2007-11-08 2009-05-14 Regents Of The University Of California Alleviating neuropathic pain with eets and seh inhibitors
WO2012054093A2 (en) * 2010-01-29 2012-04-26 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
EP2809314A4 (en) * 2012-02-01 2015-07-08 Univ California TREATMENT OF NEUROPATHIC PAIN WITH SEH INHIBITORS
US9034903B2 (en) 2012-02-01 2015-05-19 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
US10383835B2 (en) 2012-03-14 2019-08-20 The Regents Of The University Of California Treatment of inflammatory disorders in non-human mammals
PT2872501T (pt) * 2012-07-10 2016-09-06 Ares Trading Sa Derivados de pirazolil pirimidina

Also Published As

Publication number Publication date
DK3129023T3 (da) 2021-05-25
EP3129023A1 (en) 2017-02-15
ES2871027T3 (es) 2021-10-28
AU2015237245B2 (en) 2019-11-28
US10377744B2 (en) 2019-08-13
US20170174665A1 (en) 2017-06-22
CN106163521A (zh) 2016-11-23
CN106163521B (zh) 2021-02-09
AU2015237245A1 (en) 2016-08-25
EP3129023A4 (en) 2017-08-30
CN112898196A (zh) 2021-06-04
WO2015148954A1 (en) 2015-10-01
PL3129023T3 (pl) 2021-08-16
EP3129023B1 (en) 2021-02-24

Similar Documents

Publication Publication Date Title
BR112016021641A2 (pt) Potentes inibidores da epóxido hidrolase solúveis
MX2021006581A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
PH12016502586A1 (en) Lipid comprising docosapentaenoic acid
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
BR112017017727A8 (pt) Heterociclos bicíclicos como inibidores de fgfr4
SG10201806849WA (en) Cyclopropylamines as lsd1 inhibitors
ECSP17011657A (es) Conjugados de fármacos con anticuerpos anti-cdh6
EA201790575A1 (ru) Триазолопиразиноны в качестве ингибиторов pde1
BR112015019995A2 (pt) Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
EA201792157A1 (ru) Имидазопиразиноны в качестве ингибиторов pde1
EA201790442A1 (ru) Трициклические азотсодержащие соединения для лечения инфекции, вызываемой neisseria gonorrhoeae
BR112017006552A2 (pt) composições e métodos para inibir a atividade biológica de biomoléculas solúveis
MX2017001490A (es) Combinaciones de farmacos para tratar mieloma multiple.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
BR112017009289A2 (pt) métodos de administrar composições de amantadina
DOP2017000098A (es) Compuesto heterocíclico
MX2016012203A (es) Tratamiento de enfermedades colestasicas intrahepaticas.
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
UY35438A (es) Procedimiento para preparar inhibidores de la glucosilceramida sintasa.
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
BR112019006504A2 (pt) regime de dosagem de avelumabe para o tratamento de câncer
IN2014MU00916A (pt)
MX2017007245A (es) Metodos de tratamiento de la fibrosis.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2560 DE 28/01/2020.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]